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Mutations in DPAGT1 Cause a Limb-Girdle Congenital
Myasthenic Syndrome with Tubular Aggregates
Katsiaryna Belaya,1,5 Sarah Finlayson,1,2 Clarke R. Slater,3 Judith Cossins,1 Wei Wei Liu,1
Susan Maxwell,1 Simon J. McGowan,4 Siarhei Maslau,5 Stephen R.F. Twigg,6 Timothy J. Walls,7
Samuel I. Pascual Pascual,8 Jacqueline Palace,2 and David Beeson1,*
Congenital myasthenic syndromes are a heterogeneous group of inherited disorders that arise from impaired signal transmission at the
neuromuscular synapse. They are characterized by fatigable muscle weakness. We performed whole-exome sequencing to determine the
underlying defect in a group of individuals with an inherited limb-girdle pattern of myasthenic weakness.We identifyDPAGT1 as a gene
in which mutations cause a congenital myasthenic syndrome. We describe seven different mutations found in five individuals with
DPAGT1 mutations. The affected individuals share a number of common clinical features, including involvement of proximal limb
muscles, response to treatment with cholinesterase inhibitors and 3,4-diaminopyridine, and the presence of tubular aggregates in
muscle biopsies. Analyses of motor endplates from two of the individuals demonstrate a severe reduction of endplate acetylcholine
receptors. DPAGT1 is an essential enzyme catalyzing the first committed step of N-linked protein glycosylation. Our findings underscore
the importance of N-linked protein glycosylation for proper functioning of the neuromuscular junction. Using the DPAGT1-specific
inhibitor tunicamycin, we show that DPAGT1 is required for efficient glycosylation of acetylcholine-receptor subunits and for efficient
export of acetylcholine receptors to the cell surface. We suggest that the primary pathogenic mechanism of DPAGT1 mutations is
reduced levels of acetylcholine receptors at the endplate region. These individuals share clinical features similar to those of congenital
myasthenic syndrome due to GFPT1 mutations, and their disorder might be part of a larger subgroup comprising the congenital
myasthenic syndromes that result from defects in the N-linked glycosylation pathway and that manifest through impaired neuromus-
cular transmission.Congenital myasthenic syndromes (CMSs) are inherited
disorders of neuromuscular transmission.1,2 They are a
heterogeneous group of disorders in which the safety
margin for neuromuscular transmission is compromised
as a result of mutations in a series of different genes encod-
ing proteins at the neuromuscular synapse. These disorders
are characterized by fatigable muscle weakness, and the
most commonly affected muscles are ocular, bulbar, and
limb muscles. The age of onset is variable, although most
cases present with the disorder in infancy or early child-
hood. To date, mutations in 15 different genes have been
shown to lead to impaired neuromuscular transmission,
although some are limited to single case reports.1,2
Whereas most CMS-associated genes have a defined
function at the neuromuscular junction (NMJ), the
recently described GFPT1 encodes glutamine-fructose-
6-phosphate transaminase 1, which is ubiquitously ex-
pressed and is involved in the synthesis of UDP-N-acetyl-
glucosamine, a saccharide that serves as a building block
for protein and lipid glycosylation. Although the exact
role of GFPT1 in NMJ function is unknown, it is possible
that when mutated, it impairs glycosylation and, conse-
quently, the function of one or more component proteins
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The AmThere remain a number of CMS subtypes for which the
underlying mutations have not been identified. Individ-
uals with a predominant limb-girdle pattern of muscle
weakness have been found to have mutations in DOK74
(MIM 610285) and GFPT1 (MIM 138292).3 Although these
cases share several phenotypic features, muscle biopsy has
shown that the majority of individuals with GFPT1 muta-
tions have tubular aggregates, which are not seen in
muscle biopsies from individuals with DOK7-associated
CMS.5 However, tubular aggregates have been identified
in muscle biopsies of additional cases who do not have
GFPT1 mutations. Here, we performed whole-exome
capture and high-throughput sequencing to identify a
second CMS-associated mutation that underlies a limb-
girdle-type congenital myasthenia with tubular aggregates
in muscle biopsy. Ethical approval for studies on CMSs was
obtained from Oxfordshire Research Ethics Committees B
(04.OXB.017) and C (09/H0606/74).
Initially, we studied two unrelated individuals (cases 1
and 2) with tubular aggregates in muscle biopsies and
without GFPT1 mutations. We performed whole-exome
capture from 3 mg of genomic DNA by using Agilent Sure-
Select Human All Exon Kit v.2 according to the manufac-
turer’s protocol. We sequenced the captured libraries byrall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS,
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using 51 bp paired-end reads on Illumina HiSeq or
Genome Analyzer IIx platforms. We mapped sequence
data to human genome build hg19 by using Novoalign
software (Novocraft Technologies). The duplicate reads
generated as a result of PCR amplification were filtered
out, and only reads that mapped uniquely to the genome
were used for further analysis. Aligned sequence data
was visualized with GBrowse6 and the UCSC genome
browser.7 Variants were called with either Samtools8 or
Platypus9 programs. Variants were filtered out if they
were present in dbSNP13210 (unless they were annotated
as medically associated SNPs). This filtering narrowed the
list of variants to 1,574 and 1,287 variants per exome for
cases 1 and 2, respectively (see Table S1, available online).
Functional annotation of the variants with ANNOVAR
software11 allowed us to separate nonsynonymous sub-
stitutions, splicing mutations, and mutations in 30 UTRs
or 50 UTRs, further limiting the number of interesting
variants to 377 and 300 per exome for cases 1 and 2,
respectively.
CMSs are commonly inherited in an autosomal-recessive
manner. Thus, we focused on the genes that had either
homozygous variants or contained two or more heterozy-
gous variants. Among these, 34 genes had potential muta-
tions in both analyzed individuals. Further filtering of
these variants with our in-house database of 14 exomes
from cases with unrelated disorders allowed us to eliminate
all but one gene—DPAGT1 (RefSeq NM_001382.3), which
encodes dolichyl-phosphate (UDP-N-acetylglucosamine)
N-acetylglucosaminephosphotransferase 1. Case 1 had
two heterozygous nonsynonymous mutations, c.324G>C
(p.Met108Ile) and c.349G>A (p.Val117Ile), whereas case 2
had a heterozygous frameshift single-nucleotide dupli-
cation, c.699dup (p.Thr234Hisfs*116), along with the non-
synonymous mutation c.349G>A (p.Val117Ile).
We confirmed the presence of all four mutations in
the genome of analyzed individuals by using Sanger
sequencing. To determine whether DPAGT1mutations are
present in other CMS cases, we performed Sanger
sequencing of DPAGT1 on a cohort of 31 unrelated cases
of suspected CMS with varying phenotypic features, and
we identified two more individuals who had two hetero-
zygous nonsynonymous mutations in this gene. Case 3
had a combination of mutations c.358C>A (p.Leu120Met)
andc.791T>G(p.Val264Gly),whereas case4hadmutations
c.478G>A (p.Gly160Ser) and c.574G>A (p.Gly192Ser)
(Table 1). All four individuals with DPAGT1 mutations
were genetically screened for possible mutations in GFPT1
or in other known CMS-associated genes, and all proved
to be negative.
To analyze whether DPAGT1 mutations segregate with
disease, we performed Sanger sequencing of DPAGT1 in
family members. In all available samples, the mutations
displayed a perfect Mendelian inheritance pattern and
segregated with the disease (Figure 1). For case 1, no
material from family members was available for analysis.
However, because these two mutations were less than 51194 The American Journal of Human Genetics 91, 193–201, July 13, 2nucleotides (the length of each read in our sequencing
experiment) apart, we could see that each sequencing
read contained only one or the other of these mutations.
No reads contained both or none of the mutations, indi-
cating that these two mutations were present on two
different chromosomes and were thus most likely in-
herited from two different parents. For case 2, genomic
DNA was available from four unaffected siblings. Two of
the siblings were heterozygous for the frameshift muta-
tion, one was heterozygous for c.349G>A, and one sibling
had neither mutation. For case 3, each parent was hetero-
zygous for one of the mutations. Additionally, case 3 had
one affected sibling and one unaffected sibling. The
affected sibling (case 5) had the same DPAGT1 mutations
as case 3, whereas the unaffected sibling carried only one
of the mutations. For case 4, family members were not
available for analysis. Thus, the segregation of theDPAGT1
mutations is consistent with the hypothesis that the muta-
tions underlie the CMS phenotype.
None of the DPAGT1 variants described above were
present in dbSNP 13510 or the 1000 Genomes12 database.
Additionally, we checked the Exome Variant Server13 and
found that this database lists one of our mutations,
c.324G>C, but the frequency of this mutation is very
low—0.0186% (or 2 in 10,758 alleles) in the general popu-
lation or 0.0142% (1 in 7,020 alleles) in the European
American population. All identified individuals are of
European origin, and thus, the frequencies described in
the Exome Variant Server are valid for our study. Such
low frequency of the mutation incidence suggests that
themutation is present in the population in a heterozygous
state and is consistent with the notion of the mutation
being pathogenic. Thus, it is unlikely that any of the
described DPAGT1 variants are common polymorphisms;
however, they are likely to cause disease.
The duplication mutation c.699dup causes a shift in the
reading frame in the middle of DPAGT1 after residue 234
and a premature termination codon 116 amino acids after
the duplication. It is unlikely that any functional protein
can be produced from this allele. The premature stop
codon is introduced into the penultimate exon 8 (out
of 9 exons in DPAGT1). It might be that the mRNA of
this allele will be subject to nonsense-mediated decay. In
support of this, no detectable protein was produced in
HEK 293 cells transfected with a pcDNA3.1-hygro plasmid
containing the DPAGT1 c.699dup mutant (Figure 3D). All
six single-amino-acid substitutions in DPAGT1 affect resi-
dues present in conserved regions of the protein (Figure 2)
and thus might affect the wild-type function of the
protein, although Met108, Val117, and Gly160 vary in
C. elegans and yeast. To further assess whether the muta-
tions are likely to disrupt the structure and function of
the protein, we used PolyPhen2,14 which showed that all
six missense substitutions were likely to be damaging
(Table S2). Interestingly, all identified individuals had at
least one mutation in exon 3 of DPAGT1, suggesting that
the part of the protein that this exon encodes might be012
Table 1. Clinical Details of Cases with DPAGT1 Mutations
Case 1 Case 2 Case 3 Case 4 Case 5
Gender male female male female female
Current age 43 years 57 years 25 years 58 years 6 years
Age when assessed 43 years 53 years 17 years 48 years 6 years
Mutations c.324G>C
(p.Met108Ile)
and c.349G>A
(p.Val117Ile)
c.349G>A
(p.Val117Ile)
and c.699dup
(p.Thr234Hisfs*116)
c.358C>A
(p.Leu120Met)
and c.791T>G
(p.Val264Gly)
c.478G>A
(p.Gly160Ser)
and c.574G>A
(p.Gly192Ser)
c.358C>A
(p.Leu120Met)
and c.791T>G
(p.Val264Gly)
Progression stable but with
long-term fluctuations
slowly progressive some improvement
during teenage
years
slowly progressive stable in infancy and
small improvement in
childhood
Age of onset 2.5 years 7 years 0.5 years 2 years in first year
Symptoms at onset episodic difficulty
walking
falls and is unable
to keep up with
friends
hypotonia and poor
head control
abnormal gait hypotonia and delayed
motor development
Ptosis   þ (mild and fatigable)  
Ophthalmoplegia     
Wasting    (although thin) sternocleidomastoid 
Contractures     
Spine  scoliosis scoliosis  
Decrement on RNS þ þ þ þ þ
Muscle biopsy tubular aggregates tubular aggregates tubular aggregates tubular aggregates ND
Positive response to
treatment
P, D, Sa P, D P P, D P
MRC Muscle Power Grade
Face 5 5 5 5 5
Neck flexion/extension 5/4 4þ/4þ 4/5 4/5 4/4
Shoulder abduction 4 3 4 3 4
Elbow flexion/extension 4/4 4/4 4þ/4 4þ/3þ 4/4
Wrist/finger extension 4/ND 4þ/4þ 5/4 ND/ND 5/5
Finger/thumb abduction 4/ND 4þ/4þ 4/ND ND/ND 5/5
Hip flexion/extension 4/4þ 4/4þ 4/ND 4/ND 4þ/4þ
Knee flexion/extension 4þ/4 4þ/4þ 4þ/4 4/4 4þ/4þ
Ankle dorsiflexion 4 4þ 4 4 5
Single-Fiber Electromyography
Abnormal jitter þ þ þ þ ND
Blocking þ þ þ þ ND
Bold text indicates ongoing treatment. The following abbreviations are used: ND, not done; RNS, repetitive nerve stimulation; P, pyridostigmine; D, 3, 4-diami-
nopyridine; Sa, Salbutamol; and MRC, Medical Research Council.especially important for a function related to neuromus-
cular transmission.
All five cases with mutations in DPAGT1 show a charac-
teristic CMS phenotype. All had neurophysiological
features that indicate a disorder of neuromuscular trans-
mission on electromyography (EMG); such features were
a decrement on 3 Hz repetitive nerve stimulation and jitter
and blocking on single-fiber EMG (Table 1). They share
a number of clinical features that might be used for distin-The Amguishing this form of CMS. They have minimal involve-
ment of facial, ocular, and bulbar muscles—these muscle
groups can be frequently affected in many other forms of
CMS. By contrast, the most prominently affected muscles
in cases with DPAGT1 mutations are proximal limb
muscles, although some distal muscle groups can be
affected (Table 1). As is seen for GFPT1-associated CMS,15
the age of onset tends to be later than for many other
CMSs; it occurs in childhood rather than at birth or earlyerican Journal of Human Genetics 91, 193–201, July 13, 2012 195
Figure 1. Segregation of DPAGT1 Mutations
Pedigrees of the families of all affected individuals are shown together with Sanger-sequencing verification of variants for each family
member. For case 1, alignment of several representative reads generated by next-generation sequencing is shown to demonstrate that
two mutations are always present in different reads and never occur in the same read.infancy. To date, all analyzed cases have had tubular aggre-
gates present in their muscle biopsies (Table 1, Figure 3A;
see discussion below). In terms of treatment, all cases
showed a beneficial response to anticholinesterase medica-
tion, and two benefited from taking 3,4-diaminopyridine,
which increases acetylcholine release from the nerve
terminal. Thus, individuals with mutations in DPAGT1
have clinical features (which show similarities to GFPT1-
associated CMS)15 that should help distinguish them
from individuals with other forms of CMS.
DPAGT1 encodes dolichyl-phosphate (UDP-N-acetylglu-
cosamine) N-acetylglucosaminephosphotransferase 1. This
enzyme is essential for N-linked protein glycosylation.16 In
eukaryotes, N-linked protein glycosylation occurs in the
endoplasmic reticulum (ER) and starts with the assembly
of the core glycan Glc3Man9GlcNAc2 on the lipid dolichol;
the oligosaccharide is subsequently transferred from the
lipid onto the asparagine residue of nascent proteins.
DPAGT1 is a transmembrane ER protein that catalyzes
the first committed step of the core glycan assembly—
addition of GlcNAc-1-P from cytoplasmic UDP-GlcNAc to
dolichol-P. It is highly conserved in all eukaryotes and has
membrane topology that is predicted to span the ER
membrane ten times;17 mice with knocked out Dpagt1 die
shortly after implantation, demonstrating the essential
role of this gene.18196 The American Journal of Human Genetics 91, 193–201, July 13, 2To date, two reports of mutations in DPAGT1 describe
a severe congenital disorder of glycosylation type Ij19,20
(CDG-IJ [MIM 608093]). Three cases with this disorder
have been clinically characterized. One individual had
mutation c.509A>G (p.Tyr170Cys) along with an uniden-
tified splicing mutation and produced only 12% of the
wild-type DPAGT1 level.19 The other two cases were
siblings from a consanguineous family and had homozy-
gous mutation c.341C>G (p.Ala114Gly).20 The catalytic
activity of the latter mutant was reduced to 18% of that
of the wild-type level. All three CDG-IJ cases had very
severe clinical manifestations. All had delayed develop-
ment, microcephaly, and intractable seizures, and one
had mental retardation. The siblings with homozygous
mutations died within the first year of life, whereas the
other case survived beyond six years of age. All three are
also reported to have had a severe hypotonia, suggesting
that neuromuscular transmission might also have been
seriously compromised. The symptoms of the individuals
with CMSs described in this paper were limited to neuro-
muscular function, and the nonmuscle abnormalities
characteristic of CDG-IJ were not observed in any of these
cases. As of yet, we are not in a position to explain why the
symptoms in these CMS cases are different from those of
the individuals with the CDG-IJ disorder. One possibility
is that in the cases that we describe, theDPAGT1mutations012
Figure 2. DPAGT1 Structure and Conservation
Predicted transmembrane regions are shown in green. Protein alignment was performed in ClustalW2 (see Web Resources). Positions of
amino acid substitutions are shown with arrows.are less damaging to DPAGT1 function. A residual level of
protein activity might be able to provide sufficient func-
tion in tissues other than at the NMJ. It is of note that all
of our cases have a missense amino acid substitution local-
ized in exon 3, and thus, the region of the protein encoded
by this exon could have a role important for function at
the NMJ.
Different types of disorders of glycosylation are usually
diagnosed with a transferrin glycosylation assay.21 Trans-
ferrin is an abundant serum protein that normally has
two disialo-biantennary N-glycans attached to two specific
asparagine residues. In healthy individuals, the most com-
mon form of transferrin is tetrasialotransferrin. However,
when glycosylation is deficient, hyposialyated transferrin
forms are increased, especially disialotransferrin, asialo-
transferrin, monosialotransferrin, and trisialotransferrin.
The measurement of the concentration of these hypogly-
cosylated forms of transferrin is often used as a screening
tool for different forms of congenital disorders of glycosyl-
ation. One of the approaches for measuring the transferrin
glycosylation levels is by the use of column anion-ex-
change separation followed by immunoturbidimetry.21,22
When this assay was performed on the serum samples
from two of the DPAGT1 CMS cases (cases 3 and 5), both
showed abnormal levels of transferrin glycosylation:
Case 3 had 5.98% glycosylation-deficient transferrin,
and case 5 had 8.18% deficient transferrin (normal levels
are<2.6%). Both displayed an increased presence of asialo-
transferrin and disialotransferrin. These results demon-
strate that these two CMS cases have a generalized defect
in glycosylation, and they provide strong supporting
evidence that the described variants in DPAGT1 are patho-
genic. The described assay for the transferrin glycosylation
might be useful for future detection of individuals with
similar disorders. However, it is still unclear whether the
standard glycosylation assay (with isoelectric focusing)The Amwill be sufficiently sensitive to detect the changes in trans-
ferrin glycosylation occurring in DPAGT1-associated CMS
cases.
The clinical features of case 1 have been briefly described
previously23 (subject LGM2). Amotor-point muscle biopsy
(muscle vastus lateralis) has been extensively characterized
as having possible structural and functional abnormalities
of the NMJ. Labeling of the NMJs with radiolabeled
125I-a-bungarotoxin (BuTx) revealed that the number of
a-BuTx binding sites per NMJ was ten times lower in this
subject (0.24 3 107 BuTx per NMJ in the affected subject
versus 2.34 3 107 BuTx per NMJ in controls). This was
paralleled by a reduction of the amplitude of synaptic
potentials and currents.23 Ultrastructural studies of the
NMJs showed that the amount of postsynaptic folding in
the subject was five times lower than that in the control
NMJs: the average total length of the folded membrane
at each NMJ was 20.6 mm in the affected subject and
103.5 mm in the control (as illustrated in three separate
micrographs in Figure 3B). These features are characteristi-
cally seen in acetylcholine receptor (AChR)-deficiency
syndrome, in which they contribute to impaired neuro-
muscular transmission.24–27 The primary defect of reduced
postsynaptic AChR decreases the sensitivity of the post-
synaptic membrane to the transmitter acetylcholine. A
secondary effect of the loss of endplate AChR is loss of
postsynaptic folds. This would be likely to increase the
threshold for action-potential generation in the muscle
fiber by reducing both the number and availability of
voltage-gated sodium channels, which are normally con-
centrated in the folds, and reducing the electrical ampli-
fication normally provided by the high electrical resistance
of the narrow regions of cytoplasm between the folds.28 In
accordance with the results from the muscle biopsy from
case 1, a muscle biopsy from case 2 also revealed a reduc-
tion in endplate a-BuTx binding (performed in theerican Journal of Human Genetics 91, 193–201, July 13, 2012 197
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Figure 3. DPAGT1 Is Required for
AChR-Subunit Glycosylation and Receptor
Export
(A) The electron micrograph from the
muscle biopsy from case 1 shows the pres-
ence of multiple tubular aggregates.
(B) The electron micrograph from motor-
endplate regions in case 1 shows a severe
reduction of postsynaptic folding. Various
magnifications are shown.
(C) Assay for the level of a-BuTx binding to
the surface of HEK 293 cells. Cells were
transfected with 1.5 mg of expression plas-
mids with AChR subunits (2a, 1b, 1d, and
1ε) and with 4.5 mg of an empty pcDNA
vector, a pcDNA-DPAGT1-WT plasmid,
or a pcDNA-DPAGT1-c.699dup plasmid.
Sixteen hours after transfection, cells were
incubated with or without 1 mg/ml tunica-
mycin. Binding of a-BuTx was normalized
to surface expression in the absence of
tunicamycin (100%). Error bars represent
the standard error of the mean.
(D) Immunoblot of cell extracts from the
a-BuTx cell-surface-binding experiment
(above). As described, cells were trans-
fected with 1.5 mg of plasmids with AChR
subunits (2a, 1b, 1d, and 1ε) and with
4.5 mg of an empty pcDNA vector (),
a pcDNA-DPAGT1-WT (‘‘WT’’) plasmid,
or a pcDNA-DPAGT1-c.699dup (‘‘dup’’)
plasmid. Sixteen hours after transfection,
cells were incubated with5 1 mg/ml tuni-
camycin. Cell extracts were subject to im-
munoblotting and probed with antibodies
against the AChR d subunit, DPAGT1
(raised to amino acids 27–57 of DPAGT1),
or a-tubulin as a loading control. The levels
of endogenous DPAGT1 were too low to
be detected at the exposure conditions
shown.National Hospital for Neurology and Neurosurgery,
London in 1987). Thus, both analyzed biopsies show a
reduction of endplate AChR. In keeping with the loss of
endplate AChR, all the affected individuals respond to
anticholinesterase medication, and two individuals benefit
from taking 3,4-diaminopyridine; both of these medica-
tions are standard treatments for AChR deficiency.2 These
observations are consistent with the hypothesis that
DPAGT1 mutations cause a loss of endplate AChR.
Adult AChR is a pentameric receptor consisting of sub-
units 2a, 1b, 1d, and 1ε. The pentameric receptor is assem-198 The American Journal of Human Genetics 91, 193–201, July 13, 2012bled in the ER before being exported
to the plasma membrane.29 All four
subunits of AChR are N-glycosy-
lated.30 Glycosylation is required for
the insertion of AChRs into the
plasma membrane through the regu-
lation of subunit stability, folding,
assembly, and intracellular trans-
port.31,32 It is therefore possible that
in DPAGT1 mutants, AChR subunitsare abnormally glycosylated and thus fail to be exported
to the plasma membrane.
To establish whether DPAGT1 is required for AChR
export, we used an a-BuTx binding assay to measure levels
of AChR expressed on the cell surface. In this experiment,
cDNAs of 2a, 1b, 1d, and 1ε AChR subunits were trans-
fected into HEK 293 cells either with wild-type DPAGT1
or with an empty vector. The next day, the medium was
changed either to normal growth medium or to growth
medium containing 1 mg/ml tunicamycin. Forty-eight
hours after transfection, the surface expression of AChR
was measured with radioactively labeled 125I-a-BuTx.
Tunicamycin is a specific inhibitor of DPAGT133 and has
previously been shown to inhibit AChR-subunit glycosyla-
tion and export to the cell surface.34 We tested whether
overexpression of wild-type DPAGT1 could rescue this
effect of tunicamycin on AChR export. Addition of tunica-
mycin to the cells had a drastic effect on AChR export in
cells transfected with the empty vector; fewer than 20%
of the receptors were able to get to the cell surface (Fig-
ure 3C). However, cells overexpressing wild-type DPAGT1
were resistant to treatment with tunicamycin and dis-
played normal levels of AChR at the cell surface. Overex-
pression of the DPAGT1 c.699dup mutant did not restore
normal levels of the receptor that gets inserted into the
plasma membrane in the presence of the tunicamycin
inhibitor. The result is consistent with the observation
that little, if any, functional DPAGT1 was produced from
the plasmid with this mutation (Figure 3D). Immunoblot
analysis of the cell extract from these experiments showed
that glycosylation of the d AChR subunit (the most heavily
glycosylated of the four AChR subunits) was completely
lost upon treatment with tunicamycin in cells transfected
with the empty vector. However, glycosylation was par-
tially rescued when wild-type DPAGT1, but not the
DPAGT1 c.699dup (p.Thr234Hisfs*116) mutant, was over-
expressed in the cells (Figure 3D). All other missense sub-
stitutions in DPAGT1 were able to rescue inhibition with
tunicamycin (data not shown). This is consistent with
previously published papers in which it was shown that
even catalytically inactive DPAGT1 can rescue inhibition
with tunicamycin because the protein can still bind the
inhibitor and thus efficiently buffer it out.35,36 We con-
clude that DPAGT1 is indeed required for AChR export to
the cell surface, and the results are consistent with loss of
endplate AChR in the affected individuals.
A feature of the biopsy from case 1 is the presence of
numerous tubular aggregates inside themuscle (Figure 3A).
Tubular aggregates are commonly found in individuals
with GFPT1 mutations but are notably absent from the
muscles of individuals with DOK7-associated CMS; these
latter individuals have a similar predominantly limb-girdle
pattern of muscle weakness. Similar aggregates were
observed in each of the analyzed individuals with DPAGT1
mutations (Table 1). The exact structure and physiological
significance of tubular aggregates is not clear at pre-
sent. They are usually characterized as long membranous
tubules packed with different misfolded and aggregated
membrane proteins.37,38 They are believed to arise from
membranes of sarcoplasmic reticulum. Tubular aggregates
are rare and have been previously observed in certain cases
with myopathies, myotonia, or myotonic dystrophy, in
some cases with channelopathies, and in most individuals
with CMS caused by mutations in GFPT1.3,39,40 Both
DPAGT1 and GFPT1 are required for protein glycosylation,
which in turn is essential for correct protein folding and
targeting.41 It might be that in the individuals with
compromised function of DPAGT1 and GFPT1, certainThe Amcellular transmembrane and secreted proteins are not
appropriately glycosylated; this will lead to their mis-
folding and aggregation in the sarcoplasmic reticulum
and the subsequent formation of tubular aggregates.
In summary, we identify DPAGT1 as a gene in which
mutations can cause a CMS. DPAGT1, similar to GFPT1,
is involved in protein glycosylation. However, whereas
the pathogenic mechanism of GFPT1 has not been estab-
lished, we suggest that the primary pathogenic mechanism
of DPAGT1 mutations is disruption of AChR-subunit
glycosylation, inefficient export of AChR to the cell sur-
face, and consequently reduced levels of endplate AChRs.
The fact that two genes involved in the protein glycosyla-
tion pathway lead to the development of CMSs suggests
that there might be a series of such genes in which muta-
tions might affect function at the NMJ. We do not yet
know why the symptoms resulting from the mutations
we identified are restricted to muscle and the NMJ in
particular. Further study of DPAGT1 mutations will help
define the role of glycosylation for structure and function
at the neuromuscular synapse and will have potential
implications for synaptic transmission in the CNS.Supplemental Data
Supplemental Data include two tables and can be found with this
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